Eli Lilly unveils pivotal data from the star of its Dermira buyout. But can it rival Dupixent in atopic dermatitis?
It’s been just over a year and a half since Eli Lilly shelled out $1.1 billion for Dermira and its old Roche castoff lebrikizumab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
